One last chance for Merck-Glenmark Januvia mediation?
This article was originally published in Scrip
Executive Summary
The high profile Indian patent infringement litigation between Glenmark and Merck & Co over the latter's diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), appears to be at a crucial juncture, with the Delhi High Court permitting one final adjournment to the firms to revert to it on a potential settlement.